1. 799PDPhase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). (23rd October 2018) Authors: Tagawa, S T; Vallabhajosula, S; Jhanwar, Y; Hackett, A; Oromendia, C; Naiz, M J; Goldsmith, S J; Nanus, D M; Beltran, H; Molina, A M; Faltas, B; Sreekumar, J; Babich, J; Ballman, K; Bander, N H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗